June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
VEGF-A in Lacrimal gland Adenoid Cystic Carcinoma
Author Affiliations & Notes
  • Shahzan Anjum
    All India Institute of Medical Sciences, New Delhi, Delhi, India
  • Seema Sen
    All India Institute of Medical Sciences, New Delhi, Delhi, India
  • Sameer Bakhshi
    All India Institute of Medical Sciences, New Delhi, Delhi, India
  • Seema Kashyap
    All India Institute of Medical Sciences, New Delhi, Delhi, India
  • Kunzang chosdol
    All India Institute of Medical Sciences, New Delhi, Delhi, India
  • Neelam Pushker
    All India Institute of Medical Sciences, New Delhi, Delhi, India
  • Mandeep Singh Bajaj
    All India Institute of Medical Sciences, New Delhi, Delhi, India
  • Mehar Chand Sharma
    All India Institute of Medical Sciences, New Delhi, Delhi, India
  • Rachna Meel
    All India Institute of Medical Sciences, New Delhi, Delhi, India
  • Footnotes
    Commercial Relationships   Shahzan Anjum, None; Seema Sen, None; Sameer Bakhshi, None; Seema Kashyap, None; Kunzang chosdol, None; Neelam Pushker, None; Mandeep Bajaj, None; Mehar Sharma, None; Rachna Meel, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 2843. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Shahzan Anjum, Seema Sen, Sameer Bakhshi, Seema Kashyap, Kunzang chosdol, Neelam Pushker, Mandeep Singh Bajaj, Mehar Chand Sharma, Rachna Meel; VEGF-A in Lacrimal gland Adenoid Cystic Carcinoma. Invest. Ophthalmol. Vis. Sci. 2021;62(8):2843.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the status of Vascular Endothelial Growth Factor-A (VEGF-A) in lacrimal gland Adenoid cystic carcinoma (ACC) and to correlate with high risk clinicopathological features.

Methods : A retrospective analysis of 30 histopathologically proven ACC patients was undertaken. Clinicopathological features were recorded & 1-55 months follow up was available. TNM staging was done (AJCC, 8thedition). VEGF-A expression was evaluated by immunohistochemisty (IHC) (clone VG1). The association between VEGF-A and clinicopathological variables was analysed using Fisher’s exact test; survival by Kaplan-Meier and statistical analysis using log-rank test. Cox regression was performed to determine its prognostic significance.

Results : Of the 30 ACC cases, there were 15 females and males respectively with a mean age of 38±25.8 years. Large tumor size (>2 cm) was found in 86.6% (26/30) cases. The growth pattern was cribriform (n=16), solid (n=9) and mixed (n=5). Perineural invasion was present in 33.3% (10/30), intracranial extension in 16.6% (5/30) & bone erosion in 33.3% (10/30) cases. Exenteration was performed in 23.3% (7/30). Recurrence developed in 60% (18/30), systemic metastasis and death both in 20% (6/30) cases. VEGF-A overexpression was seen in 46.6% (14/30) cases. Clinicopathological correlation revealed VEGF-A to be significantly associated with solid histologic pattern (p=0.04) and intracranial extension (p=0.01). On Kaplan-Meier analysis, expression of VEGF-A (p=0.002), solid histologic pattern (p=0.004), perineural invasion (p=0.003), bone erosion (p= 0.000), T3-T4 stage (p= 0.004), intracranial extension (p= 0.01) and exenteration (p=0.01) significantly correlated with reduced disease free survival. Univariate analysis showed significant correlation of VEGF-A overexpression, solid histologic pattern, perineural invasion, bone erosion, T3-T4 stage, intracranial extension, exenteration and metastasis. On multivariate analysis VEGF-A (HR: 15.2, 95% CI: 1.9-119.4, p=0.010) and bone erosion (HR: 21.0, 95% CI: 1.7-247.8, p=0.015) were found significant prognostic factors along with metastasis (HR: 5.3, 95% CI: 1.0-26.8, p=0.04).

Conclusions : Overexpression of VEGF-A along with bone erosion and metastasis are all important poor prognostic factors in the outcome of lacrimal gland ACC. Studies on a larger cohort is necessary to further validate VEGF-A as a potential therapeutic target in the management of lacrimal gland ACC.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×